Search Within

Mark Blaine Geyer

Formats
  1. Meeting Abstract (39)
  2. Journal Article (35)
  3. Review (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Adult Leukemia (85)
  2. Center for Hematologic Malignancies (85)
  3. Department of Medicine (85)
  4. Hematologic Malignancies, Division of (85)
  5. Weinberg Fellows (85)
  6. Epidemiology and Biostatistics (29)

More Groups

People
  1. Jae Park (45)
  2. Martin Tallman (20)
  3. Mikhail Roshal (15)
  4. Renier Brentjens (15)
  5. Andriy Derkach (13)
  6. Lindsey Roeker (13)

More People

Years
  1. 2025 (3)
  2. 2024 (7)
  3. 2023 (14)
  4. 2022 (6)
  5. 2021 (8)
  6. 2020 (10)

More Years

Publications
  1. Blood (32)
  2. Leukemia and Lymphoma (8)
  3. Blood Advances (5)
  4. Haematologica (3)
  5. Journal of Clinical Oncology (3)
  6. Cytotherapy (2)

More Publications

Publishers
  1. American Society of Hematology (37)
  2. Taylor & Francis Group (9)
  3. Elsevier Inc. (6)
  4. American Society of Clinical Oncology (4)
  5. Nature Publishing Group (4)
  6. American Association for Cancer Research (3)

More Publishers

Results (85)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Venetoclax in combination with pediatric-inspired chemotherapy in adults with newly diagnosed acute lymphoblastic leukemia: Results of a phase I trial
    Meeting Abstract

    Valtis, Y. K.; Geyer, M. B.; Torres, M.; Grogan, M.; Shukla, M.; Stein, E. M.; Park, J. H.
    Blood (2023)

    Fulltext@MSK | Save
  • Despite high rates of remission, treatment of IDH-mutant AML with hypomethylating agents and venetoclax is associated with frequent treatment delays, modifications, and transfusions
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Berman, E.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Rampal, R. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Chemotherapy-sparing induction followed by consolidation and maintenance with blinatumomab and concurrent oral tyrosine kinase inhibitor therapy for newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Primary endpoint results from the BLISSPHALL study
    Meeting Abstract

    Geyer, M. B.; Mascarenhas, J.; Smith, M.; Pascual, S.; Shah, A.; Silvestrone, M. R.; Czaplinska, T.; Johnson, K.; Thompson, M. C.; Park, J. H.
    Blood (2023)

    Fulltext@MSK | Save
  • Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades
    Meeting Abstract

    Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
    Journal Article

    McCarter, J. G. W.; Nemirovsky, D.; Famulare, C. A.; Farnoud, N.; Mohanty, A. S.; Stone-Molloy, Z. S.; Chervin, J.; Ball, B. J.; Epstein-Peterson, Z. D.; Arcila, M. E.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab
    Research Letter

    Parisi, R.; Cowen, E. A.; Gu, S.; Dusza, S.; Pulitzer, M.; Geyer, M. B.; King, A. C.; Markova, A.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Lenalidomide-associated B-cell ALL: Clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
    Journal Article

    Geyer, M. B.; Shaffer, B. C.; Bhatnagar, B.; Mims, A. S.; Klein, V.; Dilip, D.; Glass, J. L.; Lozanski, G.; Hassoun, H.; Landau, H.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel
    Review

    Perissinotti, A. J.; Bishop, M. R.; Bubalo, J.; Geyer, M. B.; Goodrich, A.; Howard, S. C.; Kula, J.; Mandayam, S.; Cairo, M. S.; Pui, C. H.
    Cancer Treatment Reviews (2023)

    Fulltext@MSK | Save
  • Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients
    Journal Article

    Mahmood, S. S.; Riedell, P. A.; Feldman, S.; George, G.; Sansoterra, S. A.; Althaus, T.; Rehman, M.; Mead, E.; Liu, J. E.; Devereux, R. B.; more...
    European Heart Journal (2023)

    Fulltext@MSK | Save